Integrating pharmacogenomic testing into paired germline and somatic genomic testing in patients with cancer
Precision medicine has revolutionized clinical care for patients with cancer through the development of targeted therapy, identification of inherited cancer predisposition syndromes and the use of pharmacogenetics to optimize pharmacotherapy for anticancer drugs and supportive care medications. While germline (patient) and somatic (tumor) genomic testing have evolved separately, recent interest in paired germline/somatic testing has led to an increase in integrated genomic testing workflows. However, paired germline/somatic testing has generally lacked the incorporation of germline pharmacogenomics. Integrating pharmacogenomics into paired germline/somatic genomic testing would be an efficient method for increasing access to pharmacogenomic testing. In this perspective, the authors argue for the benefits of implementing a comprehensive approach integrating somatic and germline testing that is inclusive of pharmacogenomics in clinical practice.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Pharmacogenomics - 24(2023), 13 vom: 19. Aug., Seite 731-738 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Seligson, Nathan D [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adverse events |
|---|
| Anmerkungen: |
Date Revised 12.10.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2217/pgs-2023-0125 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361993897 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361993897 | ||
| 003 | DE-627 | ||
| 005 | 20231226090319.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/pgs-2023-0125 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1206.xml |
| 035 | |a (DE-627)NLM361993897 | ||
| 035 | |a (NLM)37702060 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Seligson, Nathan D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Integrating pharmacogenomic testing into paired germline and somatic genomic testing in patients with cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 12.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Precision medicine has revolutionized clinical care for patients with cancer through the development of targeted therapy, identification of inherited cancer predisposition syndromes and the use of pharmacogenetics to optimize pharmacotherapy for anticancer drugs and supportive care medications. While germline (patient) and somatic (tumor) genomic testing have evolved separately, recent interest in paired germline/somatic testing has led to an increase in integrated genomic testing workflows. However, paired germline/somatic testing has generally lacked the incorporation of germline pharmacogenomics. Integrating pharmacogenomics into paired germline/somatic genomic testing would be an efficient method for increasing access to pharmacogenomic testing. In this perspective, the authors argue for the benefits of implementing a comprehensive approach integrating somatic and germline testing that is inclusive of pharmacogenomics in clinical practice | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a PGx | |
| 650 | 4 | |a adverse events | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a malignancy | |
| 650 | 4 | |a precision medicine | |
| 700 | 1 | |a Kolesar, Jill M |e verfasserin |4 aut | |
| 700 | 1 | |a Alam, Benish |e verfasserin |4 aut | |
| 700 | 1 | |a Baker, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Lamba, Jatinder K |e verfasserin |4 aut | |
| 700 | 1 | |a Fridley, Brooke L |e verfasserin |4 aut | |
| 700 | 1 | |a Salahudeen, Ameen A |e verfasserin |4 aut | |
| 700 | 1 | |a Hertz, Daniel L |e verfasserin |4 aut | |
| 700 | 1 | |a Hicks, J Kevin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacogenomics |d 2000 |g 24(2023), 13 vom: 19. Aug., Seite 731-738 |w (DE-627)NLM111671396 |x 1744-8042 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:13 |g day:19 |g month:08 |g pages:731-738 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/pgs-2023-0125 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 13 |b 19 |c 08 |h 731-738 | ||